Cipla stated that the US Food and Drug Administration (USFDA) issued Form 483 with eight observations after inspecting its Pithampur-based manufacturing facility in Madhya Pradesh.
The US Food and Drug Administration (USFDA) undertook a current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility from February 6 to 17, said Cipla in its regulatory filing.
The company further added that it received 8 inspectional observations in Form 483 at the end of the inspection.
According to the company, it will work closely with the USFDA and is committed to addressing these issues comprehensively within the time frame specified.
Following this development, Cipla stock was trading 4.94% lower at Rs975 per piece, against the previous close of Rs1,025.75 on NSE. The counter opened at Rs998 and touched an intraday low of Rs955.25 so far.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.